Stoke Therapeutics (STOK) EBT Growth (3y) (2021 - 2026)

Stoke Therapeutics (STOK) EBT Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.34%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 40.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 12.01%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 86.16%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Stoke Therapeutics 1.87 Bn 1.53 Bn - -26.48%

Historic Data

Download Data
DateValue
Mar 31, 2026 -26.48%
Dec 31, 2025 20.56%
Sep 30, 2025 -10.61%
Jun 30, 2025 9.98%
Mar 31, 2025 85.58%
Dec 31, 2024 45.21%
Sep 30, 2024 -1.51%
Jun 30, 2024 -4.40%
Mar 31, 2024 -16.15%
Dec 31, 2023 -123.72%
Sep 30, 2023 -25.47%
Jun 30, 2023 -36.07%
Mar 31, 2023 -30.41%
Dec 31, 2022 -130.54%
Sep 30, 2022 -50.40%
Jun 30, 2022 -60.29%
Mar 31, 2022 -65.43%
Dec 31, 2021 -170.25%
Sep 30, 2021 -96.77%